Development of a physiologically based pharmacokinetic model of 2-methoxyethanol and 2-methoxyacetic acid disposition in pregnant rats

被引:31
作者
Hays, SM
Elswick, BA
Blumenthal, GM
Welsch, F
Conolly, RB
Gargas, ML
机构
[1] ChemRisk Serv McLaren Hart Inc, Cleveland, OH USA
[2] Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA
关键词
pharmacokinetic modeling; PBPK; 2-methoxyethanol; 2-methoxyacetic acid; pregnant rats;
D O I
10.1006/taap.1999.8836
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An accurate description of developing embryos' exposure to a xenobiotic is a desirable component of mechanism-based risk assessments for humans exposed to potential developmental toxicants during pregnancy. 2-Methoxyethanol (2-ME), a solvent used in the manufacture of semiconductors, is embryotoxic and teratogenic in all species tested including nonhuman primates. 2-Methoxyacetic acid (2-MAA) is the primary metabolite of 2-ME and the proximate embryotoxic agent, The objective of the work described here was to adapt an existing physiologically based pharmacokinetic (PBPK) model for 2-ME and 2-MAA kinetics during midorganogenesis in mice to rats on gestation days (GD) 13 and 15, Blood and tissue data were analyzed using the extrapolated PBPK model that was modified to simulate 2-ME and 2-MAA kinetics in maternal plasma and total embryo tissues in pregnant rats. The original mouse model was simplified by combining the embryos and placenta with the richly perfused tissue compact ment, The model includes a description of the growth of the developing embryo and changes in the physiology of the dam during pregnancy, Biotransformation pathways of 2-ME to either ethylene glycol (EG) or to 2-MAA were described as first-order processes based on the data collected from rats by Green et at, (Occup. Hyg, 2, 67-75, 1996), Tissue partition coefficients (PCs) for 2-ME and 2-MAA were determined for a variety of maternal tissues and the embryos. Model simulations closely reflected the biological measurement of 2-ME and 2-MAA concentrations in blood and embryo tissue following gavage or iv administration of 2-ME or 2-MAA. The PBPK model for rats as described here is well suited for extrapolation to pregnant women and for assessment of 2-MAA dosimetry under various conditions of possible human exposure to 2-ME. (C) 2000 Academic Press.
引用
收藏
页码:67 / 74
页数:8
相关论文
共 24 条
[1]  
ANDERSON CA, 1991, PSYCHOL INQ, V2, P14
[2]   THE TERATOGENICITY OF METHOXYACETIC ACID IN THE RAT [J].
BROWN, NA ;
HOLT, D ;
WEBB, M .
TOXICOLOGY LETTERS, 1984, 22 (01) :93-100
[3]   PHARMACOKINETICS OF 2-METHOXYETHANOL AND 2-METHOXYACETIC ACID IN THE PREGNANT MOUSE - A PHYSIOLOGICALLY-BASED MATHEMATICAL-MODEL [J].
CLARKE, DO ;
ELSWICK, BA ;
WELSCH, F ;
CONOLLY, RB .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1993, 121 (02) :239-252
[4]   PROTECTION AGAINST 2-METHOXYETHANOL-INDUCED TERATOGENESIS BY SERINE ENANTIOMERS - STUDIES OF POTENTIAL ALTERATION OF 2-METHOXYETHANOL PHARMACOKINETICS [J].
CLARKE, DO ;
MEBUS, CA ;
MILLER, FJ ;
WELSCH, F .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1991, 110 (03) :514-526
[5]   2-METHOXYACETIC ACID DOSIMETRY TERATOGENICITY RELATIONSHIPS IN CD-1 MICE EXPOSED TO 2-METHOXYETHANOL [J].
CLARKE, DO ;
DUIGNAN, JM ;
WELSCH, F .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1992, 114 (01) :77-87
[6]  
CORELY RA, 1994, TOXICOL APPL PHARM, V129, P61
[7]   PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF THE PREGNANT RAT - A MULTIROUTE EXPOSURE MODEL FOR TRICHLOROETHYLENE AND ITS METABOLITE, TRICHLOROACETIC-ACID [J].
FISHER, JW ;
WHITTAKER, TA ;
TAYLOR, DH ;
CLEWELL, HJ ;
ANDERSEN, ME .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1989, 99 (03) :395-414
[8]  
GREEN CE, 1996, OCCUP HYG, V2, P67
[9]   COMPARISON OF THE TERATOGENIC POTENTIAL OF INHALED ETHYLENE-GLYCOL MONOMETHYL ETHER IN RATS, MICE, AND RABBITS [J].
HANLEY, TR ;
YANO, BL ;
NITSCHKE, KD ;
JOHN, JA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1984, 75 (03) :409-422
[10]   DEVELOPMENTAL PHASE-SPECIFIC AND DOSE-RELATED TERATOGENIC EFFECTS OF ETHYLENE-GLYCOL MONOMETHYL ETHER IN CD-1 MICE [J].
HORTON, VL ;
SLEET, RB ;
JOHNGREENE, JA ;
WELSCH, F .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1985, 80 (01) :108-118